Sagent Patent-Cliff Exposure & CMS Drug Spending Portfolio

Sagent (US): 2 reconciled FDA prescription therapies, $440.7M 2024 CMS Part D & Medicaid spend, and $4,500 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies2
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2043-01-01
2024 CMS Total Public Spend$440.7M
2024 Medicare Part D Spend$299.6M
2024 Medicaid Spend$141.1M
California HCAI SB 17 FilingsSpecialty launch notice ($4,500 intro WAC)